ISR Reports - COPD Market, Treatment, and Pipeline Development Overview


Published on

A new report by ISR, provides in-depth analysis into current COPD market dynamics (including market sizing and projections) as well as a development analysis of COPD drugs in the pipeline.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

ISR Reports - COPD Market, Treatment, and Pipeline Development Overview

  1. 1. COPD: Market, Treatment and Development Overview 1 COPD: Market, Treatment and DevelopmentIn this summary…Introduction 2 OverviewMajor Sections 2Companies/Therapies/Pipelines 3Table of Contents 4List of Tables 6List of Figures 7Samples Pages 8Ordering 11Q2, 2012Length: 146 Pages, including 68Charts and GraphsPublisher: Industry StandardResearch (ISR)Valuable for:Pharma / Biotech Marketing Sales Sales Training R&DContract Sales OrganizationsContract Research Organizations This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a combined view of the COPD pipeline not available elsewhere. The purpose of this report is to give an extensive overview of the current and future COPD market and discuss the activities of the key players and some of the issues surrounding COPD drug development. Scope of the Research Decision-making Focused - COPD Disease Overview - Opportunity assessment, COPD market size - Epidemiology of COPD - Market dynamics, how products currently in the pipeline could unseat current therapies and shake-up the market - Current COPD Therapies - Identify strategic development opportunities - COPD Market Size - Enhance commercialization strategic planning - Leading COPD Companies and Products - Competitive assessment, provides a full analysis and - Clinical Development Analysis and Pipeline for COPD Drug Therapies summary of major COPD companies, including: Current products, financial summary, and R&D efforts © 2012 Industry Standard Research
  2. 2. COPD: Market, Treatment and Development Overview 2Introduction It is widely recognized that the global social and economic burden of COPD is high; affecting an estimated 64 million people worldwide. However, the availability of accurate data for COPD prevalence is hampered by variability in study methodology and both under-diagnosis and misdiagnosis of the disease. While 12 million Americans are diagnosed with COPD, it is estimated that an additional 12 million remain undiagnosed. The economic burden of COPD is tremendous. This creates a tremendous opportunity for substantial economic gains by pharmaceutical companies that can bring novel products to market. In Europe the annual economic burden of respiratory diseases is estimated to be approximately €102 billion, with COPD responsible for over half of the burden. The COPD market is currently dominated by a few therapies in a very limited number of classes which are used to manage the symptoms of COPD, but have little effect on the underlying, poorly understood disease process. The substantial unmet need associated with the disease creates significant market potential for players in the field. Indeed the COPD market is set to undergo significant change, with the recent launch of a new product class and new highly anticipated combination therapies with block- buster potential set to reach market in the near and mid-term. The patent expiration and arrival of generics of some of the fields’ key drugs will also herald change in the market.Major Report Sections 1. Chronic Obstructive Lung Disease (COPD) 2. Epidemiology of COPD a) COPD prevalence b) Future prevalence 3. Current COPD Therapies a) Current treatment options b) Unmet patient needs 4. COPD Market Size 5. Leading COPD Companies and Products a) Key players in the respiratory and COPD market 6. Clinical Development Issues for COPD Drug Therapies a) Clinical trial design requirements and selection of endpoints b) COPD development plans c) Competition in COPD arena 7. Clinical Development Pipeline a) R&D trends in the treatment of COPD b) Upcoming companies in COPD Research A full table of contents is available on page © 2012 Industry Standard Research
  3. 3. COPD: Market, Treatment and Development Overview 3Companies, Treatment Therapies, and Pipelines Leading COPD Companies The leading COPD companies were included in this analysis. Depending on information available, ISR’s report provides financial summaries, key COPD products, and COPD R&D activities for: - GlaxoSmithKline - Merck & Co - Boehringer Ingelheim - AstraZeneca - Novartis - Sunovion - Almirall - Nycomed - Forest Labs Currently Available Treatment Options Bronchodilators Therapies Non-bronchodilator Therapies - Beta2-Adrenergic Agonists - Antibiotics - Short-Acting Beta2-Adrenergic Agonists - Oral Mucolytic Therapy (SABA) - Alpha-1 Antitrypsin Augmentation - Long-Acting Beta2-Adrenergic Agonists Therapy (AAAT) (LABA) - Oxygen Therapy - Ultra-LABAs - Surgical Treatments - Antimuscarinics - Inhaled Corticosteroids (ICS) - Oral Corticosteroids - LABA and ICS Combinations - SABA and SAMA Combinations - Xanthine Derivatives - Selective Phosphodiesterase Type 4 (PDE-4) Inhibitors Upcoming Companies in COPD Treatment - Vectura - Theravance - Pearl Therapeutics - Elevation Pharmaceuitcals - Rottapharm Madaus - © 2012 Industry Standard Research
  4. 4. COPD: Market, Treatment and Development Overview 4Table of Contents To obtain the full table of contents for this report, please download our free full report preview from our website: development-overviewList of Tables To obtain the full list of tables included in this report, please download our free full report preview from our website: development-overviewList of Figures To obtain the full list of figures included in this report, please download our free full report preview from our website: development-overview © 2012 Industry Standard Research
  5. 5. COPD: Market, Treatment and Development Overview 5Sample Pages From the section entitled “COPD Prevalence: Europe” Europe with highest rates found in Italy and Germany. This does not entirely reflect data from WHO Europe on the prevalence of smoking in Europe (see Figure 2). Germany has one of the highest rates of smoking prevalence, estimated at approximately 34% which correlates with the countries high COPD prevalence, however by comparison Italy reports a smoking prevalence of only 24% but an estimated COPD prevalence as high as that of Germany. Sweden reports a high COPD prevalence but at 16% one of the lowest smoking prevalence rates in Europe (33). Figure 1: COPD Prevalence in Europe Source: European White Lung Book Figure 2. Smoking Prevalence Rates in Selected European Countries Source: © 2012 Industry Standard Research
  6. 6. COPD: Market, Treatment and Development Overview 6Sample Pages From the section entitled “R&D Trends in Treatment of COPD” Chapter 7: Clinical Development Pipeline R&D Trends in the Treatment of COPD Fixed Dose Combination Therapies The development pipeline is dominated by fixed dose combination products. These include both LABA/ICS combinations and LABA/LAMA combinations. Those in the LABA/ICS category are predominantly aimed at combining the “ultra-LABAs” with ICS in order to provide once-daily dosing. The most advanced is GSK’s Relovair, which ultimately hopes to replace the twice-daily Advair which will face generic competition in the short to mid-term. The development of once daily LABAs has brought the possibility of combination with LAMAs in one product. Several of these combinations are now in late-stage development. Both muscarinic antagonists and beta2 agonists cause bronchodilation, but by different mechanisms of action. They also have non-bronchodilator effects that can be complementary and beneficial in patients with COPD. The combination integrates two medications which are often prescribed individually to optimize disease control, into one inhaler, thus cutting the medication burden. This concept is being taken one step further by small biotech company Pearl Therapeutics who are currently investigating a triple combination LABA/LAMA/ICS. In an advance to the direct combination of two agents in one dosage form, GSK is developing a bifunctional long acting bronchodilator, GSK961081, which combines both muscarinic antagonist and beta2 agonist activities in a single molecule. The company’s aim is to combine bifunctional activity and high lung selectivity to develop a product with greater efficacy than single mechanism bronchodilators and with equal or better tolerability. The molecule could then be combined with ICS in a single dose inhaler. Novel Anti-inflammatory Therapies As the understanding of the inflammatory process which underlies COPD grows and develops it raises the possibility of targeting appropriate inflammatory mediators in order to relieve symptoms and affect the underlying disease process. By directly influencing the cellular components of inflammation or interfering with mediators which regulate the migration and activation of inflammatory cells, the inflammatory cascade can be interrupted or inactivated. New entities directed at some of these potential targets are beginning to make their way through the clinical trial © 2012 Industry Standard Research
  7. 7. COPD: Market, Treatment and Development Overview 7Sample Pages From the section entitled “Respiratory Market Size” Table 10: Drivers and Constraints on the COPD Market Market Drivers Market Constraints  Large and expanding patient population  Patent expiration on key therapies  Increased diagnosis and drug treatment  Threat of generic entry in near term  Changing views of respiratory disorders  Restrictions on healthcare budgets favour  XXXXXXXXX XXXXXXXXXXX XXXXXXXXXX generics use  XXXXX XXXXXXXXXX  XXXX XXXXXXXXX XXXX XX X XXXXXXXXX  Market with blockbuster potential  XXXX XXXXXXXX XXX X XXXXXXX XXXXX XXX  XXXXXXXX XXXXXXXXXX XXX XXX XXXX X X XXX XX XXXX XXXXXXXXXXXXXX XXXX XXXXX XX XXXX X XXXX XXXXXX XXXXXX XXXXXXXX XXXXXXX  Underserved disease with considerable XXXXXX XX XXXX XXXXXXX X XXXXXXX unmet needs  Increased bargaining power of purchasers  A number of recently approved therapies  Relatively poor understanding of the disease with growth potential process making it difficult to target new  Potential for new therapy classes in the treatments short to mid term  New drugs with new mechanisms of action in the longer term  XXXXX XXXX XXXX XXXXXX XX X XXXX XXXX XXXXX XXXXX  XXXXXXXX XXX XXXXXXXXXXX © 2012 Industry Standard Research
  8. 8. COPD: Market, Treatment and Development Overview 8Ordering Information / Licensing Options: Ordering and licensing information is available in the full report preview, free on our website: development-overviewAbout Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at, email, or follow us on twitter © 2012 Industry Standard Research